Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06523621
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle

Study Details

This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.

Key Dates

Start date
Feb 28, 2025
Status verified
Apr 2026
Primary completion
Mar 21, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Nivolumab

Primary Outcome Measure

Depth of Response [ Time Frame: From enrollment to best response; approximately 5 months after initiating nivolumab ]

Locations (1)

FacilityCityStateZIPSite coordinators
Levine Cancer InstituteCharlotteNorth Carolina28204-

Find similar trials in Charlotte, NC

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Levine Cancer Institute· Charlotte, NC

Related Studies